DRUG
Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
Status
Completed
Phase
Phase 4
Enrollment
232
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors
Interventions
Treatment arms and agents.
DRUG
Orgalutran
Timeline
From registration to results.
First posted
Jun 10, 2016
Study start
Jun 2016
Primary completion
Jul 2017
Study completion
Jul 10, 2017
Results posted
Not reported
Registry updated
Sep 13, 2017
Outcomes
What the study measures.
Primary outcomes
donor ovarian response
Time frame · 1 month
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 35 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * Oocyte donors included in the oocyte donation program of Clinica EUGIN. * 1st oocyte donation cycle at Clínica EUGIN. Exclusion Criteria: * Polycistic Ovarian syndrome (PCOs). * Estradiol levels on day 2 of menstrual cycle \>70 pg/ml. * Hormone treatments up to 3 months before the oocyte donation cycle. * Medical contraindication to the treatments used in the study
Study locations
1 registered sites.
Spain. Showing up to 24 locations stored in the fast local snapshot.
Clinica Eugin
Barcelona, Spain
Publications
Results and literature.
Related trials
More studies on Ganirelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
University of Delaware · Estrogen · Premenopause
Phase 4
Recruiting
30
2026-07
Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
ART Fertility Clinics LLC · Healthy
Not applicable
Not yet recruiting
20
2026-05
INTEnsity of ovariaN Stimulation and Embryo Quality
Fundación Santiago Dexeus Font · Infertility
Phase 4
Completed
110
2026-04
Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.
Instituto Bernabeu · IVF
Phase 4
Completed
150
2026-03
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
Hanoi Medical University · Infertility (IVF Patients) · Embryo Morphokinetics
Not applicable
Recruiting
148
2026-02
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
University Hospital, Ghent · Ovarian Stimulation · Quality of Life
Phase 4
Recruiting
60
2025-12
DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT
Tam Anh TP. Ho Chi Minh General Hospital · Diminished Ovarian Reserve
Not applicable
Recruiting
730
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.